Journal of Breast Disease最新文献_第4页

Diagnostic Value of Contrast-enhanced Digital Mammography Versus Contrast-enhanced MRI for Detecting Residual Disease after Neoadjuvant Chemotherapy for Breast Cancer 数字乳腺造影与磁共振造影对乳腺癌新辅助化疗后残留病变的诊断价值

Journal of Breast Disease Pub Date : 2020-10-27 DOI: 10.21203/rs.3.rs-65472/v1

Eun Young Kim, J. Yun, Y. Park, Chan Heun Park, Mi-ri Kwon, J. Moon, I. Youn, Y. Choi, S. Kook

{"title":"Diagnostic Value of Contrast-enhanced Digital Mammography Versus Contrast-enhanced MRI for Detecting Residual Disease after Neoadjuvant Chemotherapy for Breast Cancer","authors":"Eun Young Kim, J. Yun, Y. Park, Chan Heun Park, Mi-ri Kwon, J. Moon, I. Youn, Y. Choi, S. Kook","doi":"10.21203/rs.3.rs-65472/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-65472/v1","url":null,"abstract":"\u0000 Background: Preoperative evaluation of breast cancer using contrast-enhanced digital mammography (CEDM) as a possible alternative to contrast-enhanced magnetic resonance imaging (CEMRI) has gained acceptance. Our aim is to compare the diagnostic performance of CEDM and CEMRI for chemotherapeutic response in breast cancer patients who underwent neoadjuvant chemotherapy (NAC).Methods: From November 2017 to October 2018, 30 patients with invasive carcinoma who performed both CEDM and CEMRI were included. Residual malignancy sizes after NAC were compared with histopathological results. The diagnostic performances for detecting residual cancers were compared using Lin concordance and Pearson correlation coefficients.Results: Thirty patients were included for the analysis. Mean tumor size after NAC was 1.22 cm (range: 0–7.0 cm) for CEDM and 1.13 cm (range: 0–5.1cm) for CEMRI compared with 1.89 cm (range: 0–12.0 cm) at final pathology measurement. Sensitivity for identifying residual lesion was for CEDM and CEMRI is as follows (CEDM 62.5%, 95% CI 40.6–81.2, CEMRI 66.7%, 95% CI 44.7–84.4). The positive predictive value (PPV) for residual lesion was 93.8% (95% CI 69.8–99.8) for CEDM and 88.9% (95% CI 65.3–98.6) for CEMRI. CEDM had a mean difference from pathology measurement of 0.668 cm, with a concordance coefficient of 0.202 and a Pearson correlation coefficient of 0.231 (p=0.220).Conclusions: Diagnostic value of CEDM for detecting residual tumor extent after NAC was comparable to that of CEMRI.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128209179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological Significance of SMAD4 Expression in Breast Cancer 乳腺癌中SMAD4表达的临床病理意义

Journal of Breast Disease Pub Date : 2019-12-31 DOI: 10.14449/jbd.2019.7.2.52

J. Woo, M. Chung, S. Paik

{"title":"Clinicopathological Significance of SMAD4 Expression in Breast Cancer","authors":"J. Woo, M. Chung, S. Paik","doi":"10.14449/jbd.2019.7.2.52","DOIUrl":"https://doi.org/10.14449/jbd.2019.7.2.52","url":null,"abstract":"Purpose: SMAD4 is a member of the SMAD family and acts as a central mediator of transforming growth factor beta signaling. Little is known about SMAD4 expression and its prognostic significance in breast cancer. We evaluated the clinicopathological and prognostic significance of SMAD4 expression in breast cancer. Methods: Two hundred and fifty-five patients with invasive ductal carcinoma of the breast from 2000 to 2008 were retrospectively analyzed. We investigated SMAD4 expression using a tissue microarray-based immunohistochemical assay and evaluated the association between SMAD4 and prognosis of breast cancer. Results: High SMAD4 expression was positively associated with early stage (p=0.009), estrogen receptor positivity (p=0.026), and human epidermal growth factor receptor 2 negativity (p=0.001). A significant difference in overall survival (OS) was associated with high SMAD4 expression in patients with T1 stage tumors (hazard ratio: 0.459, p=0.024). Conclusion: High SMAD4 expression was correlated with several favorable prognostic factors and was associated with favorable OS in T1 stage breast cancer. SMAD4 in breast cancer has potential prognostic significance, and further investigations and understanding about SMAD4 expression are needed.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125117884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer 弱阳性激素受体乳腺癌和三阴性乳腺癌的治疗效果

Journal of Breast Disease Pub Date : 2019-06-30 DOI: 10.14449/JBD.2019.7.1.1

Minjoo Yoon, J. Rhu, B. Song, B. Chae, T. Yoo

{"title":"Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer","authors":"Minjoo Yoon, J. Rhu, B. Song, B. Chae, T. Yoo","doi":"10.14449/JBD.2019.7.1.1","DOIUrl":"https://doi.org/10.14449/JBD.2019.7.1.1","url":null,"abstract":"Purpose: In breast cancer, response to endocrine therapy depends on estrogen receptor and progesterone receptor status. However, poor prognosis is conferred on patients with hormone receptor (HR)-positive breast cancer. We aimed to examine weakly positive HR breast cancer by comparing weakly positive HR to strongly positive HR and negative HR breast cancer. Methods: We examined the clinical and biological features of 1,496 women with breast cancer, and these patients were categorized according to HR status as weakly positive, strongly positive, and negative HR breast cancer. Results: In this study, among 1,496 patients with breast cancer, negative HR breast cancer was found in 374, weakly positive HR breast cancer in 90 and strongly positive HR breast cancer in 1,032 patients. Our multivariate analysis showed that there were differences in T stage, tumor–node–metastasis stage, vascular invasion, histologic grade and type, and Ki-67 index. Patients with weakly positive HR breast cancer had an increased risk of death and recurrence compared with those with strongly positive HR breast cancer and had similar prognosis as patients with negative HR breast cancer. Conclusion: Patients with weakly positive HR breast cancer received endocrine therapy because they were regarded as having positive HR breast cancer. However, their prognosis of overall survival and relapse-free survival was similar to that in patients with negative HR breast cancer. Therefore, we need to closely observe and consider active treatment for patients with weakly positive breast cancer.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127131189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics 根据生物学亚型和临床特征的乳腺癌器官特异性复发或转移模式

Journal of Breast Disease Pub Date : 2019-06-30 DOI: 10.14449/JBD.2019.7.1.30

Jaeyoon Kim, Yujin Lee, T. Yoo, Jungbin Kim, Jonghee Hyun, I. Park, Hyunjin Cho, K. Yang, Byung-Noe Bae, Ki Hwan Kim, Kyeongmee Park, G. Gwak

引用次数: 5

Oncologic Results of Breast Conserving Surgery under Procedural Sedation in Elderly Patients 老年患者手术镇静下保乳手术的肿瘤学结果

Journal of Breast Disease Pub Date : 2019-06-30 DOI: 10.14449/JBD.2019.7.1.9

Jeeyeon Lee, J. Jung, W. Kim, Y. Lim, Ryu Kyung Lee, K. Kwak, H. Park

{"title":"Oncologic Results of Breast Conserving Surgery under Procedural Sedation in Elderly Patients","authors":"Jeeyeon Lee, J. Jung, W. Kim, Y. Lim, Ryu Kyung Lee, K. Kwak, H. Park","doi":"10.14449/JBD.2019.7.1.9","DOIUrl":"https://doi.org/10.14449/JBD.2019.7.1.9","url":null,"abstract":"Purpose: Although surgery is the most frequently implemented treatment modality for breast cancer, many older patients with breast cancer are underor untreated because of their high incidence of postoperative complications. We assessed the efficacy and safety of breast surgery under procedural sedation in older patients (aged >70 years) by comparing selected clinical and oncologic factors after surgery for breast cancer under general anesthesia versus procedural sedation. Methods: Of 79 older patients with breast cancer, 49 underwent breast-conserving surgery, 30 under general anesthesia and 19 under procedural sedation, and relevant clinical and oncologic variables were compared and analyzed between groups. Results: The mean age was younger in the general anesthesia group and the mean operation time, hospital stay, and fasting time shorter in the procedural sedation group. There were no statistically significant differences in oncologic results between the two groups during follow-up. Conclusion: Breast surgery under procedural sedation is a safe and effective means of reducing tumor burden in older patients with breast cancer when their American Society of Anesthesiologists (ASA) physical status indicates a high risk of life-threatening perioperative complications associated with general anesthesia. And we also found that the oncologic results may be not inferior to same procedure under general anesthesia.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"135 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114311324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Clinical Implication of Intraoperative Sonography in Localized Excision Biopsy for Mammographic Microcalcifications 术中超声在乳腺微钙化局部切除活检中的临床意义

Journal of Breast Disease Pub Date : 2019-06-30 DOI: 10.14449/JBD.2019.7.1.16

J. Choi, D. Cho, Jiwoong Jung

引用次数: 0

Prognostic Factors in Patients with Locally Advanced Breast Cancer Treated by Neoadjuvant Chemotherapy 局部晚期乳腺癌新辅助化疗的预后因素分析

Journal of Breast Disease Pub Date : 2019-06-30 DOI: 10.14449/JBD.2019.7.1.23

Min Jaegal, Shin Jae Kang, Y. Ryu, J. Cho, M. Park, Jung-han Yoon

{"title":"Prognostic Factors in Patients with Locally Advanced Breast Cancer Treated by Neoadjuvant Chemotherapy","authors":"Min Jaegal, Shin Jae Kang, Y. Ryu, J. Cho, M. Park, Jung-han Yoon","doi":"10.14449/JBD.2019.7.1.23","DOIUrl":"https://doi.org/10.14449/JBD.2019.7.1.23","url":null,"abstract":"Purpose: Neoadjuvant chemotherapy (NAC) has become the standard treatment for patients with locally advanced breast cancer. The purpose of this study was to evaluate prognosis according to molecular subtype and clinicopathologic factors in patients with locally advanced breast cancer treated by NAC. Methods: We retrospectively analyzed the medical records of 91 patients with breast cancer who underwent NAC followed by surgery between January 2005 and January 2010. The patients were classified into four molecular subtype groups: luminal A, luminal B, HER2 enriched, and triple negative (TN). Results: Thirty-five (38%) patients had luminal A, 13 (14%) patients luminal B, 22 (24%) patients HER2 enriched and 21 (21%) patients TN breast cancer. Patients with TN breast cancer tended to be more than 50 years of age and to have a higher histologic grade. There were statistically significant differences according to ypN stage (ypN0 vs. ypN1–3; p=0.019, 5-year disease-free survival [DFS]; p=0.005, 5-year overall survival [OS]) and lymphovascular invasion (LVI) (p=0.003, 5-year DFS; p=0.006, 5-year OS) in the univariate analysis. In the multivariate analysis, LVI was a significant factor in 5-year DFS (odds ratio 2.145, 95% confidence interval 1.064–4.324, p=0.033). There was no significant difference among molecular subtypes in DFS (p=0.161) or OS (p=0.084). Conclusion: LVI was associated with prognosis in patients with locally advanced breast cancer treated by NAC and surgery. However, molecular subtype had no effect on 5-year DFS or OS.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"371 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115180805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Development of an Excel Program for the Updated Eighth American Joint Committee on Cancer Breast Cancer Staging System 更新第八届美国癌症乳腺癌分期系统联合委员会的Excel程序开发

Journal of Breast Disease Pub Date : 2018-12-31 DOI: 10.14449/JBD.2018.6.2.35

Jaewon Jo, Eui Tae Kim, J. Min, M. Chang

{"title":"Development of an Excel Program for the Updated Eighth American Joint Committee on Cancer Breast Cancer Staging System","authors":"Jaewon Jo, Eui Tae Kim, J. Min, M. Chang","doi":"10.14449/JBD.2018.6.2.35","DOIUrl":"https://doi.org/10.14449/JBD.2018.6.2.35","url":null,"abstract":"Purpose: The eighth American Joint Committee on Cancer staging system for breast cancer was recently published to more accurately predict the prognosis by adding biomarkers such as estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2. However, this system is very complicated and difficult to use by clinicians. The authors developed a program to aid in setting up the staging system and confirmed its usefulness by applying it to theoretical combinations and actual clinical data. Methods: The program was developed using the Microsoft Excel Macro. It was used for the anatomic, clinical and pathological prognostic staging of 588 theoretical combinations. The stages were also calculated the stages using 840 patients with breast cancer without carcinoma in situ or distant metastasis who did not undergo preoperative chemotherapy. Results: The anatomic, clinical and pathological prognostic stages were identical in 240 out of 588 theoretical combinations. In the actual patients’ data, stages IB and IIIB were more frequent in clinical and pathological prognostic stages than in the anatomic stage. The anatomic stage was similar to the clinical prognostic stage in 58.2% and to the pathological prognostic stage in 61.9% of patients. Oncotype DX changed the pathological prognostic stage in 2.1% of patients. Conclusion: We developed a program for the new American Joint Committee on Cancer staging system that will be useful for clinical prognostic prediction and large survival data analysis.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"712 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127701405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study 人表皮生长因子受体2阳性乳腺癌诊断方法的临床意义:回顾性研究

Journal of Breast Disease Pub Date : 2018-12-31 DOI: 10.14449/JBD.2018.6.2.60

B. Kim, Joon Jeong, W. Han, T. Yoon, M. Seong, J. Jung, S. Jung, Jina Lee, W. Sun

引用次数: 0

Primary Angiosarcoma of the Breast: A Case Report 乳腺原发性血管肉瘤1例报告

Journal of Breast Disease Pub Date : 2018-12-31 DOI: 10.14449/JBD.2018.6.2.73

Rachel Kim, H. Lee, H. Park

引用次数: 4